2023

  1. Ustekinumab vs Infliximab in CD

  2. Ritlecitinib and Brepocitinib in UC

  3. Infliximab or azathioprine withdrawal in CD

  4. Diverting ileostomy closure after pouch construction

  5. Tofacitinib in acute severe ulcerative colitis

  6. Phase 2 trial, guselkumab in Crohn’s disease efficacy and safety at week 48

  7. Allopurinol-thiopurine versus standard thiopurine in patients with IBD

  8. LAG-3 depleting antibody GSK2831781 in UC

  9. Upadacitinib in Crohn’s disease induction and maintenance

  10. Adalimumab increased interval in CD